Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) - Investment analysts at HC Wainwright decreased their FY2025 EPS estimates for Alpha Tau Medical in a research note issued to investors on Monday, March 17th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.53) per share for the year, down from their prior estimate of ($0.50). HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Alpha Tau Medical's current full-year earnings is ($0.45) per share.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13).
Alpha Tau Medical Price Performance
DRTS traded up $0.01 on Wednesday, hitting $2.61. The company had a trading volume of 21,600 shares, compared to its average volume of 48,967. The company's fifty day moving average price is $3.20 and its 200 day moving average price is $2.80. The stock has a market cap of $182.50 million, a price-to-earnings ratio of -6.07 and a beta of 0.87. Alpha Tau Medical has a 1-year low of $1.75 and a 1-year high of $4.39.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC grew its position in shares of Alpha Tau Medical by 188.7% in the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock valued at $127,000 after purchasing an additional 26,800 shares during the last quarter. Northern Trust Corp boosted its stake in Alpha Tau Medical by 112.6% during the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock valued at $151,000 after purchasing an additional 25,770 shares during the period. Finally, Levin Capital Strategies L.P. grew its holdings in Alpha Tau Medical by 2.3% in the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock valued at $975,000 after buying an additional 7,189 shares during the last quarter. Institutional investors own 2.65% of the company's stock.
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Featured Stories
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
